Last reviewed · How we verify
ABBV-453
BTK inhibitor
BTK inhibitor Used for Non-Hodgkin lymphoma.
At a glance
| Generic name | ABBV-453 |
|---|---|
| Sponsor | AbbVie |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AbbVie's ABBV-453 is a Bruton's tyrosine kinase (BTK) inhibitor, which is a type of kinase inhibitor that targets the BTK enzyme. BTK is involved in the activation of B cells, and its inhibition has been shown to be effective in treating certain types of non-Hodgkin lymphoma.
Approved indications
- Non-Hodgkin lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) (PHASE1, PHASE2)
- A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (PHASE1)
- A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-453 CI brief — competitive landscape report
- ABBV-453 updates RSS · CI watch RSS
- AbbVie portfolio CI